NCT01833663View on ClinicalTrials.gov

Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Overactive BladderPostmenopausal DisorderUrination Disorders
Interventions
DRUG

Solifenacin Succinate Tablets

DRUG

Estrogen

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Astellas Pharma China, Inc.

INDUSTRY

collaborator

Beijing CAT Science Co., Ltd.

UNKNOWN

lead

Peking Union Medical College Hospital

OTHER

NCT01833663 - Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women | Biotech Hunter | Biotech Hunter